Black Diamond Therapeutics (BDTX) reported a third-quarter 2026 net loss of $10.0 million, or $0.17 per basic and diluted share, compared with a $8.5 million loss a year earlier. The company ended the quarter with approximately $102.0 million in cash, cash equivalents and investments.
The company reported updated Phase 2 silevertinib data in frontline EGFR non-classical mutation NSCLC and said FDA feedback supports its planned registrational Phase 3 program, which it expects could begin in the second quarter of 2027.
- Phase 2 intention-to-treat population of 43 patients recorded 60% ORR, 93% disease control rate and median progression-free survival of 15.0 months.
- Among 16 patients with untreated brain metastases, CNS objective response rate was 86% in seven RANO-BM evaluable patients.
- Research and development expense was $7.0 million, while general and administrative expense was $5.1 million.
- Black Diamond expects its cash position to fund operations into the second half of 2028.
- The planned Phase 3 trial would enroll 300 patients with EGFR-NCMs and untreated brain metastases.
$BDTX Hedge Fund Activity
We have seen 66 institutional investors add shares of $BDTX stock to their portfolio, and 62 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 2,810,248 shares (+253.9%) to their portfolio in Q2 2026, for an estimated $5,198,958
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 1,695,980 shares (+72.7%) to their portfolio in Q2 2026, for an estimated $3,137,563
- DEFILADE CAPITAL MANAGEMENT, L.P. added 1,674,999 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,098,748
- MACKENZIE FINANCIAL CORP removed 844,835 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $1,562,944
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 569,008 shares (-68.2%) from their portfolio in Q2 2026, for an estimated $1,052,664
- WINTON GROUP LTD removed 538,259 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $995,779
- D. E. SHAW & CO., INC. removed 498,432 shares (-76.0%) from their portfolio in Q2 2026, for an estimated $922,099
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.